Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients.

Touzot M, Lefebvre T, Roux A, Maheas C, Ridel C, Puy H, Karim Z.

Nephrology (Carlton). 2019 Jul;24(7):751-757. doi: 10.1111/nep.13485. Epub 2019 Apr 25.

PMID:
30175513
2.

Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Vale L, Wallace S, MacLeod A.

Cochrane Database Syst Rev. 2002;(4):CD003895. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003895.

PMID:
12519614
3.

Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.

Khosroshahi HT, Shoja MM, Tubbs RS, Estakhri R, Ardalan MR.

Transplant Proc. 2007 May;39(4):1051-3.

PMID:
17524889
4.

[Anemia management in haemodialysis. EuCliD database in Spain].

Avilés B, Coronel F, Pérez-García R, Marcelli D, Orlandini G, Ayala JA, Rentero R.

Nefrologia. 2002;22(6):555-63. Spanish.

5.
6.

Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Pennington S, Vale L, Wallace S, MacLeod A.

Cochrane Database Syst Rev. 2001;(4):CD003266. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003266.

PMID:
11687180
7.

Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.

Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S.

Ther Apher Dial. 2014 Oct;18(5):421-6. doi: 10.1111/1744-9987.12161. Epub 2014 Jan 24.

PMID:
24456328
8.

Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.

Shinzato T, Abe K, Furusu A, Harada T, Shinzato K, Miyazaki M, Kohno S.

Med Sci Monit. 2008 Sep;14(9):CR431-7.

PMID:
18758412
9.

Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.

Albertazzi A, Di Liberato L, Daniele F, Battistel V, Colombi L.

Int J Artif Organs. 1998 Jan;21(1):12-8.

PMID:
9554820
10.

Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group.

Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A, Downs K, Szer J, Turner J, Worthington R.

Bone Marrow Transplant. 1995 Jan;15(1):129-34.

PMID:
7742745
11.

[Influence of long-term treatment with human recombinant erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia].

Nieszporek T, Kokot F, Wiecek A, Marcinkowski W, Rudka R, Trembecki J.

Pol Arch Med Wewn. 1995 Dec;94(6):488-94. Polish.

PMID:
8618811
12.

Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.

Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI, Mohsin S.

Saudi J Kidney Dis Transpl. 2015 Jan;26(1):19-25.

13.

Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients.

Takasawa K, Tomosugi N, Takaeda C, Maeda T, Ueda N.

Nephron Extra. 2014 Apr 16;4(1):55-63. doi: 10.1159/000362212. eCollection 2014 Jan.

14.

Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients.

El Said HW, Abou Seif KH, Ahmed YS, Abou Elleil HA, El Said TW, Behairy MA, Mohamed MM, Ahmed FA.

Nephrology (Carlton). 2018 Apr;23(4):323-330. doi: 10.1111/nep.13010.

PMID:
28130911
15.
16.

Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin.

Goyal H, Mohanty S, Sharma M, Rani A.

Indian J Nephrol. 2017 Jan-Feb;27(1):44-50. doi: 10.4103/0971-4065.179301.

17.

Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.

Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T.

PLoS One. 2017 Jun 29;12(6):e0179608. doi: 10.1371/journal.pone.0179608. eCollection 2017.

18.

Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.

Taylor JE, Peat N, Porter C, Morgan AG.

Nephrol Dial Transplant. 1996 Jun;11(6):1079-83.

PMID:
8671972
19.

Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.

El Sewefy DA, Farweez BA, Behairy MA, Yassin NR.

Int Urol Nephrol. 2019 Feb;51(2):325-334. doi: 10.1007/s11255-018-2062-z. Epub 2019 Jan 2.

PMID:
30600440
20.

Supplemental Content

Support Center